Search
Sodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigational[L30598] It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter [A251445] and a metabolite of the inhibitory neurotransmitter GABA.
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigationalGlatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. … [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017.
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with
Chlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones.
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalIt is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.
Anser anser feather
go.drugbank.com/drugs/DB10422ApprovedAnser anser feather is used in allergenic testing.
Mixtures: Animal Allergens, Feather Mix, Animal Allergens, Feather MixIva annua pollen
go.drugbank.com/drugs/DB10927ApprovedIva annua pollen is the pollen of the Iva annua plant. Iva annua pollen is mainly used in allergenic testing.
Mixtures: Pollens - Weeds, Marshelder/Poverty Mix, Pollens - Weeds, Marshelder/Poverty MixSpectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnIt is active against gram-negative bacteria and used for the treatment of gonorrhea.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalIt was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to